Vincent T. Metzger

Vincent T. Metzger

Auto-generated profile, based on publicly available information

Vincent T. Metzger

Division of Translational Informatics, University of New Mexico Health Sciences Center, Albuquerque, NM, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
KKKeith J Kelleher
Keith J Kelleher
TSTimothy K Sheils
Timothy K Sheils
SMStephen L Mathias
Stephen L Mathias
JYJeremy J Yang
Jeremy J Yang
VMVincent T Metzger
Vincent T Metzger
TOTudor I Oprea
Tudor I Oprea
The Illuminating the Druggable Genome (IDG) project aims to improve our understanding of understudied proteins and our ability to study them in the context of disease biology by perturbing them with small molecules, biologics, or other therapeutic modalities. Two main products from the IDG effort are the Target Central Resource Database (TCRD) (http://juniper.health.unm.edu/tcrd/), which curates and aggregates information, and Pharos (https://pharos.nih.gov/), a web interface for fusers to extract and visualize data from TCRD. Since the 2021 release, TCRD/Pharos has focused on developing visualization and analysis tools that help reveal higher-level patterns in the underlying data. The current iterations of TCRD and Pharos enable users to perform enrichment calculations based on subsets of targets, diseases, or ligands and to create interactive heat maps and UpSet charts of many types of annotations. Using several examples, we show how to address disease biology and drug discovery questions through enrichment calculations and UpSet charts.


17 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
PKPraveen Kumar
Praveen Kumar
VMVincent T. Metzger
Vincent T. Metzger
SPSwastika T. Purushotham
Swastika T. Purushotham
PKPriyansh Kedia
Priyansh Kedia
CBCristian G. Bologa
Cristian G. Bologa
JYJeremy J. Yang
Jeremy J. Yang
Background: Biomedical knowledge graphs (KGs), such as the Data Distillery Knowledge Graph (DDKG), capture known relationships among entities (e.g., genes, diseases, proteins), providing valuable insights for research. However, these relationships are typically derived from prior studies, leaving potential unknown associations unexplored. Identifying such unknown associations, including previously unknown disease-associated genes, remains a critical challenge in bioinformatics and is crucial for advancing biomedical knowledge. Methods: Traditional methods, such as linkage analysis and genome-wide association studies (GWAS), can be time-consuming and resource-intensive. This highlights the need for efficient computational approaches to identify or predict new genes using known disease-gene associations. Recently, network-based methods and KGs, enhanced by advances in machine learning (ML) frameworks, have emerged as promising tools for inferring these unexplored associations. Given the technical limitations of the Neo4j Graph Data Science (GDS) machine learning pipeline, we developed a novel machine learning pipeline called KG2ML (Knowledge Graph to Machine Learning). This pipeline utilizes our Positive and Unlabeled (PU) learning algorithm, PULSNAR (Positive Unlabeled Learning Selected Not At Random), and incorporates path-based feature extraction from ProteinGraphML. Results: KG2ML was applied to 12 diseases, including Bipolar Disorder, Coronary Artery Disease, and Parkinson’s Disease, to infer disease-associated genes not explicitly recorded in DDKG. For several of these diseases, 14 out of the 15 top-ranked genes lacked prior explicit associations in the DDKG but were supported by literature and TINX (Target Importance and Novelty Explorer) evidence. Incorporating PULSNAR-imputed genes as positives enhanced XGBoost classification, demonstrating the potential of PU learning in identifying hidden gene-disease relationships. Conclusion: The observed improvement in classification performance after the inclusion of PULSNAR-imputed genes as positive examples, along with the subject matter experts’ (SME) evaluations of the top 15 imputed genes for 12 diseases, suggests that PU learning can effectively uncover disease-gene associations missing from existing knowledge graphs (KGs). By integrating KG data with ML-based inference, our KG2ML pipeline provides a scalable and interpretable framework to advance biomedical research while addressing the inherent limitations of current KGs.

27 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DMDaniall Masood
Daniall Masood
MKMariia Kim
Mariia Kim
JVJeet Vora
Jeet Vora
RKRobel Kahsay
Robel Kahsay
PMPatrick McNeeley
Patrick McNeeley
RMRaja Mazumder
Raja Mazumder
Biomarkers are essential tools for disease detection, risk assessment, therapeutic monitoring, and precision medicine. However, biomarker data are dispersed across heterogeneous resources, inconsistently reported in the literature, and rarely standardized for computational use. This fragmentation limits reproducibility, cross-study integration, and the discovery of novel biomarker and disease relationships. We developed BiomarkerKB, a knowledgebase designed to harmonize and integrate biomarker information under a standardized data model. The model follows the FDA-NIH BEST biomarker definition and captures both core fields (biomarker entity, disease/condition, exposure agent) and contextual metadata (specimen, biomarker role, evidence, provenance). Biomarker data and related annotations were either curated from publications or collected from public resources (e.g., OpenTargets, GWAS Catalog, ClinVar, CIViC, OncoMX) and were also contributed by the Common Fund Data Coordinating Centers and the Early Detection Research Network (EDRN). Standardization was achieved using ontologies and reference resources such as Disease Ontology, UBERON, UniProtKB, and HUGO Gene Nomenclature Committee (HGNC) gene symbols. BiomarkerKB data were ingested into a Neo4j-based knowledge graph and integrated with the Common Fund Data Ecosystem (CFDE) Knowledge Graph. The initial release of BiomarkerKB contains over 200,000 biomarker-disease associations spanning genes, proteins, metabolites, glycans, and chemical elements. The knowledge graph comprises more than 300,000 nodes and 1.2 million edges, enabling structured exploration of biomarker relationships within CFDE data as demonstrated through the knowledge graph query-based use cases presented in this study. A publicly accessible web portal ( https://biomarkerkb.org ) provides keyword search, filtering, data downloads, and access to graph visualization to support both researchers and computational analyses. BiomarkerKB addresses a critical gap in biomarker informatics by providing an integrated, FAIR (Findable, Accessible, Interoperable, and Reusable), and unified framework for biomarker knowledge exploration and discovery.

15 June 2026 in medRxiv
Verified
Preprint
Open access
MPManjil M. Pradhan
Manjil M. Pradhan
RURajesh Upadhayaya
Rajesh Upadhayaya
SWSarah C. Wenyon
Sarah C. Wenyon
AVAlexandria Viszolay
Alexandria Viszolay
MRMelissa Rethlefsen
Melissa Rethlefsen
SMScott A. Malec
Scott A. Malec
Background: Systematic reviews of observational studies are central to causal inference in chronic disease epidemiology but are increasingly limited by the scale of the literature and heterogeneity in confounder control. There is a need for transparent, open methods that reduce screening burden and make reported exposures, outcomes, and covariates comparable across studies. Objective: To develop and evaluate modular LLM-based pipelines, LitScreen and VarEx, that automate study screening and variable extraction for observational systematic reviews across multiple use cases, including hypertension as a primary exposure with Alzheimer’s disease and related dementias (ADRD) as outcomes, and posttraumatic stress disorder (PTSD) as the exposure with self-harm, self-injury, and suicidality as outcomes. Methods and Materials: We built an end-to-end workflow in which reproducible MEDLINE via Ovid queries yield RIS corpora that are processed by LitScreen, a three-phase screening pipeline combining abstract-level evidence extraction, criterion-wise inclusion adjudication with high-recall gates, and full-text retrieval-augmented verification. Screened-in articles enter VarEx, a retrieval-augmented extraction pipeline that identifies role-specific passages and performs evidence-grounded extraction and semantic classification of exposures, outcomes, and covariates into predefined categories aligned with Metaconfoundr. Performance was evaluated on six labeled SYNERGY datasets and expert-annotated hypertension-to-ADRD and education-to-dementia corpora using precision, recall, F 1 , a strict score requiring correct variable identity and category, and time-per-reference estimates. Results: In the primary hypertension-to-ADRD reference set, VarEx achieved covariate-level precision of 0.80, recall of 0.79, and F 1 of 0.76, with classification accuracy of 0.97 and similar performance for education-to-dementia and SYNERGY validation datasets. LitScreen preserved high recall while excluding most ineligible records and reduced total screening and extraction time by roughly 80–90 percent relative to manual review baselines by routing only uncertain or borderline citations to full-text verification. Conclusion: A retrieval-augmented LLM framework can automate major components of screening and variable extraction for observational systematic reviews, generating reusable structured covariate inventories that integrate with causal confounder assessment tools and substantially improve the efficiency and reproducibility of evidence synthesis, while remaining an assistant to, rather than a replacement for, human reviewers.